Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed non-small cell lung cancer

  * Stage IIIB (by pleural effusion only) or stage IV disease
  * No predominately squamous cell carcinoma

    * Mixed tumors will be categorized by predominant cell type
* Must have completed 4 courses of platinum-based, doublet chemotherapy and bevacizumab\*, has no disease progression, and meets the following criteria:

  * Platinum agent may have included carboplatin or cisplatin
  * Second agent may have included paclitaxel, docetaxel, gemcitabine hydrochloride, vinorelbine ditartrate, or pemetrexed disodium
  * A change in the platinum doublet is acceptable provided the following are true:

    * Basis for change was toxicity rather than disease progression
    * Total number of courses of any platinum doublet plus bevacizumab was 4
  * At least 3 of 4 courses must have included bevacizumab NOTE: \*Patients age 70 and over may have completed 4 courses of single-agent chemotherapy plus bevacizumab; single agent chemotherapy may have included paclitaxel, docetaxel, gemcitabine hydrochloride, vinorelbine ditartrate, or pemetrexed disodium
* No brain metastases by brain MRI or head CT scan

PATIENT CHARACTERISTICS:

* ECOG performance status 0-1
* Bilirubin ≤ 1.25 times upper limit of normal (ULN)
* AST and ALT ≤ 2.5 times ULN
* Creatinine ≤ 1.5 times ULN
* Absolute neutrophil count ≥ 1500/mm³
* Platelet count ≥ 100,000/mm³
* INR ≤ 1.5 times ULN
* Urine protein:creatinine ratio ≤ 1
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment
* No history of gross hemoptysis (defined as \> ½ teaspoon of bright red blood)
* No inadequately controlled hypertension (defined as blood pressure \> 150/100 mm Hg on antihypertensive medications)
* No significant traumatic injury within the past 28 days
* No condition requiring continuous administration of systemic corticosteroids
* No medical condition that would preclude study treatment
* No medical comorbidities, including any of the following:

  * Unstable angina
  * Congestive heart failure ≥ grade 2
  * Myocardial infarction within the past 6 months
  * Stroke within the past 6 months
  * Peripheral vascular disease ≥ grade 2 within the past 6 months

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No prior systemic chemotherapy in the metastatic setting, except for 4 courses of platinum-based, doublet chemotherapy plus bevacizumab in the first-line setting

  * Prior adjuvant, neoadjuvant, or combined modality chemoradiation for localized non-small cell lung cancer allowed provided ≥ 6 months elapsed before metastatic recurrence
* At least 28 days since prior major surgical procedure
* No prior antiangiogenic drug, including AMG 706, CP-547, 632, vatalanib, AZD2171, thalidomide, sorafenib tosylate, or sunitinib malate
* No other concurrent investigational drugs
* No concurrent grapefruit juice or products containing grapefruit
* No other concurrent anticancer agents, including chemotherapy and biological agents
* No concurrent major surgical procedure
* No concurrent therapeutic coagulation comprising warfarin, heparin, or low molecular weight heparin

  * Low-dose warfarin (e.g., 1 mg/day) for prophylaxis of central venous catheter thrombosis allowed
* No chronic daily acetylsalicylic acid (\> 325 mg/day) or other full-dose nonsteroidal anti-inflammatory drug with antiplatelet activity